What is Telo Genomics Corp?
, a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions, primarily in Canada.
TDSGF · Verdict
Moderate reward · moderate risk
TDSGF stands out on volatility and balance sheet, but watch the cash flow signal.
Based on 88% data coverage
TDSGF · Verdict
Top decile vs peers
Current ratio 2.25
Weak vs peers
-52001% return on equity
Earnings +8.8% CAGR
Model-based scoring. For information only — not financial advice.
, a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions, primarily in Canada. The company's TeloView platform measures the 3D structure and spatial organization of telomeres to inform on genetic and molecular characteristics that are predictive of genomic instability, identify specific disease mechanisms, predict disease risks, and determine effective treatments. The company is listed on the OTCQB in USA, operating in the Healthcare sector, with a market capitalisation of 3.85M.
The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are moderate, consistent with typical market exposure.
For informational purposes only. Not financial advice.